Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report.
Current therapeutic modalities for ovarian cancer such as chemotherapy, radiotherapy and surgery have been reported to yield only marginal success in improving survival rates of patients and have associated adverse effects. We report here a case of recurrent stage IV ovarian cancer, treated with cell-based autologous immune enhancement therapy (AIET) along with chemotherapy and followed up for 18 months. A 54-year-old female was diagnosed with a recurrence of ovarian carcinoma 1 year after initial surgical removal followed by chemotherapy for stage IIIC ovarian carcinoma. When diagnosed in 2010 with recurrence, she had liver and spleen metastases with a CA-125 level of 243 U/ml and a stage IV clinical status. Six infusions of AIET using autologous in vitro expanded and activated natural killer (NK) cells (CD3-CD56+) and activated T lymphocytes (CD3+CD56+) were administered in combination with 6 cycles of chemotherapy with carboplatin and doxorubicin. Following this treatment, CA-125 decreased to 4.7 U/ml along with regression of the metastatic lesions and an improved quality of life. No adverse reactions were reported after the AIET transfusions. Eighteen months of follow-up revealed a static nonprogressive disease. Combining AIET with chemotherapy and other conventional treatments has been found to be effective in our experience, as reported earlier, even in patients with advanced ovarian cancer, and we recommend this strategy be considered in treating similar cases.
Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India.
Sadananda Rao
SR
Manjunath
Ganapathi
G
Ramanan
Vidyasagar Devaprasad
VD
Dedeepiya
Hiroshi
H
Terunuma
Xuewen
X
Deng
Subramani
S
Baskar
Rajappa
R
Senthilkumar
Paramasivam
P
Thamaraikannan
Thangavelu
T
Srinivasan
Senthilkumar
S
Preethy
Samuel J K
SJ
Abraham